Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end

Fulcrum Therapeutics, Inc.

2025-Q3 EPS reported -$0.87

Cash, equivalents and marketable securities $200.6M; cash runway into 2028.
Net loss $19.6M in Q3 2025 versus $21.7M in Q3 2024; R&D spend $14.3M.
12 mg dose cohort of Phase 1b PIONEER trial showed dose-dependent HbF increase and VOC reduction.
Enrollment completed in 20 mg dose cohort (n=12); data expected by year-end 2025.
Plans to submit IND for bone marrow failure syndromes (DBA, 5q-, etc.) in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.